Shop by goal

Popular compounds

GHK-Cu Copper Peptide

GLP1-RC-RT

Research resources

Orforglipron: A Research Guide to the First Oral Non-Peptide GLP-1 Receptor Agonist

Short answer: orforglipron (LY3502970) is Eli Lilly’s once-daily oral GLP-1 agonist — and the key word is small molecule , not a peptide . That is why it can be a tablet taken with no food or water restriction, and why it is far cheaper to make at scale. Phase 3 ATTAIN-1 reported ~ 12.4% mean weight loss at 72 weeks at the top dose; ATTAIN-2 (diabetes) ~10.5% with HbA1c down ~1.8%. Lilly has triggered global regulatory submissions, but it has no marketing authorisation anywhere as of mid-2026. Because it is not a peptide, it sits outside New-U’s research catalogue. Part of our next obesity-research wave overview.

Plain-English summary. Orforglipron is an unapproved, investigational drug. The FDA, MHRA and EMA have not authorised it. It is a small molecule , a different chemical class from the research peptides New-U catalogues. This page is general information, not legal or medical advice; do not use unapproved compounds on people.

What orforglipron actually is — and why “non-peptide” is the headline

Semaglutide, tirzepatide and retatrutide are all peptides — chains of amino acids. Peptides are normally destroyed in the gut, which is why they are injected (or, for oral semaglutide, packaged with absorption enhancers and dosed under strict empty-stomach rules). Orforglipron is different: it is a small molecule that happens to fit and activate the GLP-1 receptor. Small molecules:

Survive the digestive tract, so a plain once-daily tablet works — with no food or water restrictions .

Are cheaper and easier to manufacture at population scale than peptides or antibody conjugates.

Have no cold-chain requirement, simplifying global distribution.

Its developmental code is LY3502970 . The chemistry and trial detail are indexed under PubMed: orforglipron / LY3502970.

Mechanism: same receptor, different key

Orforglipron acts on the same GLP-1 receptor as the injectable peptides — suppressing appetite, slowing gastric emptying and improving glucose-dependent insulin secretion. The difference is purely the molecule doing the activating: a designed small-molecule agonist rather than a peptide analogue of GLP-1 itself. Same biology downstream; radically different manufacturing and delivery upstream.

The ATTAIN Phase 3 evidence

Trial Population Result (top dose) ATTAIN-1 (72 wks, n=3,127) Obesity / overweight + comorbidity ~−12.4% (~27.3 lbs) vs ~−0.9% placebo ATTAIN-2 Obesity / overweight + type-2 diabetes ~−10.5% (~22.9 lbs); HbA1c ~−1.8%

In ATTAIN-1 all three doses (6 mg, 12 mg, 36 mg once daily) met the primary endpoint, with dose-dependent secondary endpoints (proportions reaching ≥10%, ≥15% and ≥20% loss, plus waist-circumference reductions). The safety profile was consistent with the GLP-1 class — mostly mild-to-moderate gastrointestinal events. Following the Phase 3 readouts, Eli Lilly triggered global regulatory submissions.

Why a 12% pill can beat a 20% injection. On raw magnitude, the injectable dual and triple agonists out-lose orforglipron. But a daily tablet with no cold chain, lower cost and no needle could reach far more people — so its public-health footprint may exceed its per-patient percentage. Access, not just efficacy, is the orforglipron story.

How orforglipron compares

Compound Class Route Best documented mean weight loss Status Orforglipron Small molecule Oral, daily ~12.4% / 72 wks Submissions filed Oral semaglutide Peptide Oral, daily (restricted) Varies by dose / trial Approved (diabetes) Semaglutide (injectable) Peptide SC, weekly ~14.9% / 68 wks Approved Tirzepatide Peptide SC, weekly ~20.9% / 72 wks Approved

Orforglipron and research compounds

This is the one compound in the next-wave set that is not a peptide , so it falls outside a research-peptide catalogue entirely. New-U does not sell orforglipron , and any “research orforglipron” listing should be treated with caution as it is a proprietary small molecule, not a reference peptide. The verifiable GLP-1-class research peptides New-U does catalogue are:

Semaglutide — the GLP-1 single-agonist peptide.

Tirzepatide and retatrutide — the dual and triple agonists.

Each ships as a sealed, lyophilised reference peptide verified to >99% HPLC purity, with the per-batch Certificate of Analysis published online — research use only . For the broader oral-vs-injectable debate, see oral vs injectable GLP-1 research.

Frequently Asked Questions

What is orforglipron? Eli Lilly’s investigational once-daily oral GLP-1 agonist (LY3502970) — a small molecule, not a peptide.

Is it a peptide? No — it is a small molecule, which is why it works as a daily tablet and is cheap to manufacture at scale.

Is orforglipron approved? No. As of mid-2026 there is no marketing authorisation, though Lilly has filed global regulatory submissions.

How much weight loss? ~12.4% mean at 72 weeks (ATTAIN-1, top dose); ~10.5% in the diabetes trial.

Does New-U sell it? No — it is a small molecule outside a research-peptide catalogue. New-U carries the GLP-1-class reference peptides (semaglutide, tirzepatide, retatrutide).

Primary sources & further reading

Eli Lilly — Orforglipron Phase 3 results & regulatory submissions

The Lancet — Orforglipron in type-2 diabetes (ATTAIN-2), Phase 3 (2025)

U.S. National Library of Medicine — PubMed: orforglipron / LY3502970

ClinicalTrials.gov — ATTAIN / ACHIEVE programmes

U.S. FDA — FDA (no orforglipron approval as of publication)

External links are provided for research reference only; New-U is not affiliated with the cited organisations and links carry no endorsement either way.

From the Lab - Peptides on LinkedIn & Facebook

Lab-Verified GLP-1-Class Research Peptides

Orforglipron is a small molecule, but the GLP-1-class research peptides — semaglutide, tirzepatide and retatrutide — are catalogued by New-U as sealed 10-vial packs of lyophilised reference peptide, independently verified by Janoshik and Freedom Diagnostics for >99% HPLC purity, with the per-batch Certificate of Analysis published online. Research use only - all claims made on this site are for testing and research use only.

Research-grade · >99% HPLC purity · COA per lot

Buy research peptides from New-U Research Compounds

Lab-verified by Janoshik Analytical (RP-HPLC + ESI-MS), sealed vials, discreet tracked worldwide shipping. Research use only - all claims made on this site are for testing and research use only.

PRECISION. PURITY. PERFORMANCE.

Research peptides. Third-party Certificates of Analysis (Janoshik Analytical & Freedom Diagnostics) are published on the website. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research